Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer.
The last earnings update was 55 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Tocagen. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Tocagen's earnings available for a low price, and how does
this compare to other companies in the same industry?
Tocagen's earnings are expected to grow significantly at over 20% yearly.
Tocagen's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Tocagen's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Martin J. Duvall, also known as Marty, has been Chief Executive Officer at Tocagen Inc. since November 02, 2016. Mr. Duvall served as Chief Commercial Officer and Executive Vice President of Ariad Pharmaceuticals Inc. from December 2013 to May 31, 2016 and served as its Senior Vice President of Commercial Operations since September 2011 to December 2013. He served as Senior Vice President and General Manager, oncology at Merck and & Co., Inc. He served as Senior Vice President of Global Marketing & International Commercial Operations at Abraxis BioScience, Inc. since May 2009. Mr. Duvall served as Senior Vice President of Commercial Strategy & Development of MGI Pharma Inc. from 2007 to 2008 and also served as its Senior Vice President for Commercial Operations from November 29, 2004 to 2006. Mr. Duvall served as Chief Business Officer of Morphotek, a subsidiary of Eisai Corporation of North America. Previously, Mr. Duvall served for nearly 19 years in a number of commercial roles at Sanofi-Aventis and its predecessor companies. He served as Vice President, Team Leader, Taxotere & New Cytotoxics, Global Medical and Marketing, at Aventis Pharmaceuticals, where he provided strategic leadership for oncology products. He holds more than 30 years of experience in oncology drug development and commercialization at mid-stage and global pharmaceutical companies, including building numerous successful oncology teams. During his 18 years at Aventis Pharmaceuticals and its predecessor companies, he served in a variety of sales and marketing roles with increasing strategic responsibility. He has been a Director at Tocagen Inc. since November 02, 2016. Mr. Duvall received his BA degree in chemistry from Muhlenberg College, his MA degree in chemistry from Johns Hopkins University and his MBA from the University of Kansas.
Marty's compensation has increased whilst company is loss making.
Marty's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Tocagen management team is about average.
CEO & Director
Co-Founder & Director
Executive VP & CFO
Co-Founder and Executive VP of Research & Pharmaceutical Development
Senior Vice President of Regulatory Affairs & Quality Assurance
VP and Head of Commercial & Medical Affairs
Senior Vice President of Clinical Development
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Tocagen board of directors is about average.
Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company’s lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.